Search

Search Constraints

You searched for: Author/Creator Hellemans, Peter

Search Results

1. A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies. Issue 12 (2nd December 2018)

2. Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study. Issue 2 (28th January 2023)

6. Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6. Issue 5 (18th September 2020)

7. Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma. Issue 7 (2nd July 2016)

8. Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment*. Issue 1 (2nd January 2017)

9. Stable isotope‐labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults. (15th January 2016)